Baldwin Investment Management LLC Purchases 3,159 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Baldwin Investment Management LLC increased its stake in Johnson & Johnson by 21.5% through the purchase of an additional 3,159 shares, bringing its total holdings to 17,857 shares valued at approximately $2.96 million.
• Recent earnings data indicate that Johnson & Johnson reported an EPS of $2.77, surpassing expectations, with revenues of $23.74 billion, marking a year-over-year increase of 5.8%.
• The company announced a quarterly dividend of $1.30, with an ex-dividend date set for August 26, representing a 3.09% yield based on an annualized rate of $5.20.

Baldwin Investment Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 21.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 17,857 shares of the company's stock after purchasing an additional 3,159 shares during the period. Baldwin Investment Management LLC's holdings in Johnson & Johnson were worth $2,961,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Norden Group LLC boosted its holdings in shares of Johnson & Johnson by 37.9% in the 1st quarter. Norden Group LLC now owns 35,786 shares of the company's stock valued at $5,935,000 after buying an additional 9,833 shares during the last quarter. Werba Rubin Papier Wealth Management increased its position in shares of Johnson & Johnson by 16.4% in the first quarter. Werba Rubin Papier Wealth Management now owns 2,421 shares of the company's stock valued at $401,000 after acquiring an additional 341 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Johnson & Johnson by 9.0% in the first quarter. Mackenzie Financial Corp now owns 3,383,687 shares of the company's stock worth $561,151,000 after buying an additional 278,081 shares in the last quarter. Atlas Legacy Advisors LLC boosted its position in shares of Johnson & Johnson by 30.8% during the first quarter. Atlas Legacy Advisors LLC now owns 2,272 shares of the company's stock worth $377,000 after acquiring an additional 535 shares during the last quarter. Finally, Inlet Private Wealth LLC raised its position in Johnson & Johnson by 0.7% in the 1st quarter. Inlet Private Wealth LLC now owns 24,574 shares of the company's stock worth $4,075,000 after purchasing an additional 175 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 1.0%

JNJ stock traded down $1.69 during mid-day trading on Thursday, reaching $165.57. The company's stock had a trading volume of 3,363,663 shares, compared to its average volume of 9,022,795. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The business's 50 day moving average price is $156.93 and its 200 day moving average price is $156.30. The company has a market cap of $398.74 billion, a price-to-earnings ratio of 17.69, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.82 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.14%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.